Cruzain: The path from target validation to the clinic

Advances in Experimental Medicine and Biology

Volumn 712, Issue , 2011, Pages 100-115

  Sajid, Mohammed ^a   Robertson, Stephanie A ^b   Brinen, Linda S ^b,c   McKerrow, James H ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(4 CHLOROPHENYL)CARBONYL] N 1 [2 (PHENYLSULFONYL)ETHYL]PENTYL CYCLOHEXANECARBOXAMIDE; 3 [4 [1,2 DIMETHYL 1 [(QUINOLIN 6 YLMETHYL)AMINO]PROPYL] 1H 1,2,3 TRIAZOL 1 YL]HEPTAN 2 ONE; BENZNIDAZOLE; BENZOYLARGINYLALANINE FLUOROMETHYL KETONE; BENZOYLPHENYLALANYLALANINE FLUOROMETHYL KETONE; BENZOYLTYROSYLALANINE FLUOROMETHYL KETONE; CRUZIPAIN; CYSTEINE PROTEINASE INHIBITOR; K 777; NIFURTIMOX; PLACEBO; TETRAFLUOROPHENOXY METHYL KETONE; UNCLASSIFIED DRUG; CRUZAIN, TRYPANOSOMA CRUZI; CYSTEINE PROTEINASE; DIPEPTIDE; N PIP PHENYLALANINE HOMOPHENYLALANINE VINYL SULFONE PHENYL; N-PIP-PHENYLALANINE-HOMOPHENYLALANINE-VINYL SULFONE PHENYL; PROTOZOAL PROTEIN; VINYL DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; BIOCHEMISTRY; CHAGAS DISEASE; CLINICAL PATHWAY; CRUZAIN GENE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; HEART INJURY; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; PARASITE SURVIVAL; PARASITE TRANSMISSION; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; MOLECULAR GENETICS; PARASITOLOGY; REPRODUCIBILITY; REVIEW; TRANSLATIONAL RESEARCH;

AMINO ACID SEQUENCE; CHAGAS DISEASE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; HUMANS; MOLECULAR SEQUENCE DATA; PROTOZOAN PROTEINS; REPRODUCIBILITY OF RESULTS; TRANSLATIONAL RESEARCH; VINYL COMPOUNDS;

EID: 80053308901     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-8414-2_7     Document Type: Article

References (87)

1. Chagas C. Nova entidade morbida do homen. Resumo greal dos estudos estiologicos e clinicos. Mem Inst Oswaldo Cruz 1911; 3:219-275
2. Wilson LS, Strosberg AM, Barrio K. Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models. Am J Trop Med Hyg 2005; 73:901-910
3. Rodriques Coura J, de Castro SL. CoMFA and HQSAR of acylhydrazide cruzain inhibitors. Mem Inst Oswaldo Cruz 2002; 97:3-24
4. Duschak VG, Couto AS. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Pat Antiinfect Drug Discov 2007; 2:19-51
5. Rivera G, Bocanegra-Garcia V, Ordaz-Pichardo C et al. New therapeutic targets for drug design against Trypanosoma cruzi, advances and perspectives. Curr Med Chem 2009; 16:3286-3293
6. Moreira DR, Leite AC, dos Santos RR et al. Approaches for the development of new anti-Trypanosoma cruzi agents. Curr Drug Targets 2009; 10:212-231
7. Itow S, Camargo EP. Proteolytic activites in cell extracts ofTrypanosoma cruzi. J Protozool 1977; 24:591-595
8. Avila JL, Casanova MA, Avila A et al. Acid and neutral hydrolases in Trypanosoma cruzi. Characterization and assay J Protozool 1979; 26:304-311
9. Bontempi E, Martinez J, Cazzulo JJ. Subcellular localization of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 1989; 33:43-47
10. Cazzulo JJ, Couso R, Raimondi A et al. Further characterization and partial amino acid sequence of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 1989; 33:33-41
11. Rangel HA, Araujo PM, Repka D et al. Trypanosoma cruzi: isolation and characterization of a proteinase. Exp Parasitol 1981; 52:199-209
12. Lalmanach G, Lecaille F, Chagas JR et al. Inhibition of trypanosomal cysteine proteinases by their propeptides. J Biol Chem 1998; 273:25112-25116
13. Huete-Perez JA, Engel JC, Brinen LS et al. Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif. J Biol Chem 1999; 274:16249-16256
14. Cazzulo JJ, Hellman U, Couso R et al. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Mol Biochem Parasitol 1990; 38:41-48
15. Duschak VG, Couto AS. Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Curr Med Chem 2009; 16:3174-3202
16. Barboza M, Duschak VG, Fukuyama Y et al. Structural analysis of the N-glycans of the major cysteine proteinase ofTrypanosoma cruzi. Identification of sulfated high-mannose type oligosaccharides. Febs J 2005; 272:3803-3815
17. Labriola C, Sousa M, Cazzulo JJ. Purification ofthe major cysteine proteinase (cruzipain) from Trypanosoma cruzi by affinity chromatography. Biol Res 1993; 26:101-107
18. Barboza M, Duschak VG, Cazzulo JJ et al. Presence of sialic acid in N-linked oligosaccharide chains and O-linked N-acetylglucosamine in cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Mol Biochem Parasitol 2003; 127:69-72
19. Cazzulo JJ, Martinez J, Parodi AJ et al. On the posttranslational modifications at the C-terminal domain ofthe major cysteine proteinase (cruzipain) from Trypanosoma cruzi. FEMS Microbiol Lett 1992; 79:411-416
20. Parodi AJ, Labriola C, Cazzulo JJ. The presence of complex-type oligosaccharides at the C-terminal domain glycosylation site of some molecules of cruzipain. Mol Biochem Parasitol 1995; 69:247-255
21. Martinez J, Campetella O, Frasch AC et al. The reactivity of sera from chagasic patients against different fragments of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, suggests the presence of defined antigenic and catalytic domains. Immunol Lett 1993; 35:191-196
22. Tomas AM, Kelly JM. Stage-regulated expression of cruzipain, the major cysteine protease of Trypanosoma cruzi is independent of the level of RNA1. Mol Biochem Parasitol 1996; 76:91-103
23. Fampa P, Lisboa CV, Jansen AM et al. Protease expression analysis in recently field-isolated strains of Trypanosoma cruzi: a heterogeneous profile of cysteine protease activities between TC I andTC II major phylogenetic groups. Parasitology 2008; 135:1093-1100
24. Campetella O, Henriksson J, Aslund L et al. The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. Mol Biochem Parasitol 1992; 50:225-234
25. Martinez J, Cazzulo JJ. Anomalous electrophoretic behaviour of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi in relation to its apparent molecular mass. FEMS Microbiol Lett 1992; 74:225-229
26. Cazzulo JJ. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease. Curr Top Med Chem 2002; 2:1261-1271
27. Sajid M, McKerrow JH. Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 2002; 120:1-21
28. Martinez J, Henriksson J, Rydaker M et al. Genes for cysteine proteinases from Trypanosoma rangeli. FEMS Microbiol Lett 1995; 129:135-141
29. Lima AP, Tessier DC, Thomas DY et al. Identification ofnew cysteine protease gene isoforms in Trypanosoma cruzi. Mol Biochem Parasitol 1994; 67:333-338
30. Eakin AE, Mills AA, Harth G et al. The sequence, organization and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. J Biol Chem 1992; 267:7411-7420
31. McGrath ME, Eakin AE, Engel JC et al. The crystal structure of cruzain: a therapeutic target for Chagas' disease. J Mol Biol 1995; 247:251-259
32. Judice WA, Cezari MH, Lima AP et al. Comparison ofthe specificity, stability and individual rate constants with respective activation parameters for the peptidase activity of cruzipain and its recombinant form, cruzain, from Trypanosoma cruzi. Eur J Biochem 2001; 268:6578-6586
33. Alves LC, Melo RL, Cezari MH et al. Analysis ofthe S(2) subsite specificities ofthe recombinant cysteine proteinases CPB ofLeishmania mexicana and cruzain ofTrypanosoma cruzi, using fluorescent substrates containing nonnatural basic amino acids. Mol Biochem Parasitol 2001; 117:137-143
34. Harris JL, Backes BJ, Leonetti F et al. Rapidand general profiling ofprotease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci USA 2000; 97:7754-7759
35. Del Nery E, Juliano MA, Lima AP et al. Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi. J Biol Chem 1997; 272:25713-25718
36. Eakin AE, McGrath ME, McKerrow JH et al. Production ofcrystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. J Biol Chem 1993; 268:6115-6118
37. Souto-Padron T, Campetella OE, Cazzulo JJ et al. Cysteine proteinase in Trypanosoma cruzi: immunocytochemical localization and involvement in parasite-host cell interaction. J Cell Sci 1990; 96:485-490
38. Soares MJ, Souto-Padron T, De Souza W. Identification of a large prelysosomal compartment in the pathogenic protozoon Trypanosoma cruzi. J Cell Sci 1992; 102:157-167
39. Parussini F, Duschak VG, Cazzulo JJ. Membrane-bound cysteine proteinase isoforms in different developmental stages of Trypanosoma cruzi. Cell Mol Biol 1998; 44:513-519
40. Nascimento AE, de Souza W. High resolution localization of cruzipain and Ssp4 in Trypanosoma cruzi by replica staining label fracture. Biol Cell 1996; 86:53-58
41. Aparicio IM, Scharfstein J, Lima AP. A new cruzipain-mediated pathway of human cell invasion by Trypanosoma cruzi requires trypomastigote membranes. Infect Immun 2004; 72:5892-5902
42. Bontempi E, Cazzulo JJ. Digestion ofhuman immunoglobulin G by the major cysteine proteinase (cruzipain) from Trypanosoma cruzi. FEMS Microbiol Lett 1990; 58:337-341
43. Krettli AU, Weisz-Carrington P, Nussenzweig RS. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin Exp Immunol 1979; 37:416-423
44. Scharfstein J, Monteiro AC, Schmitz V et al. Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway. Biol Chem 1998; 389:1015-1024
45. Scharfstein J, Lima AP. Roles of naturally occurring protease inhibitors in the modulation of host cell signaling and cellular invasion by Trypanosoma cruzi. Subcell Biochem 2008; 47:140-154
46. Scharfstein J. Parasite cysteine proteinase interactions with alpha 2-macroglobulin or kininogens: differential pathways modulating inflammation and innate immunity in infection by pathogenic trypanosomatids. Immunobiology 2006; 211:117-125
47. Yokoyama-Yasunaka JK, Pral EM, Oliveira Junior OC et al. Trypanosoma cruzi: identification of proteinases in shed components of trypomastigote forms. Acta Trop 1994; 57:307-315
48. Harth G, Andrews N, Mills AA et al. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol 1993; 58:17-24
49. Meirelles MN, Juliano L, Carmona E et al. Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro. Mol Biochem Parasitol 1992; 52:175-184
50. Engel JC, Doyle PS, Hsieh I et al. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Exp Med 1998; 188:725-734
51. Caffrey CR, Scory S, Steverding D. Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr Drug Targets 2000; 1:155-162
52. Campetella O, Martinez J, Cazzulo JJ. A major cysteine proteinase is developmentally regulated in Trypanosoma cruzi. FEMS Microbiol Lett 1990; 55:145-149
53. Judice WA, Puzer L, Cotrin SS et al. Carboxydipeptidase activities of recombinant cysteine peptidases. Cruzain of Trypanosoma cruzi and CPB of Leishmania mexicana. Eur J Biochem 2004; 271:1046-1053
54. Cazzulo JJ, Cazzulo Franke MC, Martinez J et al. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Biophys Acta 1990; 1037:186-191
55. Reis FC, Costa TF, Sulea T et al. The propeptide ofcruzipain-a potent selective inhibitor ofthe trypanosomal enzymes cruzipain and brucipain and of the human enzyme cathepsin F. Febs J 2007; 274:1224-1234
56. Santos CC, Sant'anna C, Terres A et al. Use of proteolytic enzymes as an additional tool for trypanosomatid identification. J Cell Sci 2005; l 118:901-915
57. Santos CC, Scharfstein J, Lima AP. Phytomonas serpens: cysteine peptidase inhibitors interfere with growth, ultrastructure and host adhesion. Parasitol Res 2006; 99:323-324
58. Ramos AM, Duschak VG, Gerez de Burgos NM et al. Trypanosoma cruzi: cruzipain and membrane-bound cysteine proteinase isoform(s) interacts with human alpha(2)-macroglobulin and pregnancy zone protein. Exp Parasitol 2002; 100:121-130
59. Cazzulo JJ, Stoka V, Turk V. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. Biol Chem 1997; 378:1-10
60. Lima AP, Almeida PC, Tersariol IL et al. Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J Biol Chem 2002; 277:5875-5881
61. Guinazu N, Pellegrini A, Carrera-Silva EA et al. Immunisation with a major Trypanosoma cruzi antigen promotes pro-inflammatory cytokines, nitric oxide production and increases TLR2 expression. Int J Parasitol 2007; 37:1243-1254
62. Schnapp AR, Eickhoff CS, Scharfstein J et al. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Microbes Infect 2002; 4:805-813
63. Cazorla SI, Becker PD, Frank FM et al. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 2008; 76:324-333
64. Schnapp AR, Eickhoff CS, Sizemore D et al. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun 2002; 70:5065-5074
65. Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 2009; 8:921-935
66. Engel JC, Doyle PS, Palmer J et al. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Cell Sci 1998; 111:597-606
67. Kerr ID, Lee JH, Farady CJ et al. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem 2009; 284:25697-25703
68. Choe Y, Brinen LS, Price MS et al. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorg Med Chem 2005; 13:2141-2156
69. Huang L, Brinen LS, Ellman JA. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain. Bioorg Med Chem 2003; 11:21-29
70. Gillmor SA, Craik CS, Fletterick RJ. Structural determinants of specificity in the cysteine protease cruzain. Protein Sci 1997; 6:1603-1611
71. Brak K, Kerr ID, Barrett KT et al. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for chagas disease chemotherapy. J Med Chem 2010; 53:1763-1773
72. Bryant C, Kerr ID, Debnath M et al. Novel nonpeptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett 2009; 19:6218-6221
73. Choe Y, Leonetti F, Greenbaum DC et al. Substrate profiling ofcysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem 2006; 281:12824-12832
74. Brinen LS, Hansell E, Cheng J et al. A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease. Structure 2000; 8:831-840
75. Kerr ID, Lee JH, Pandey KC et al. Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. J Med Chem 2009; 52:852-857
76. Krantz A, Copp LJ, Coles PJ et al. Peptidyl (acyloxy)methyl ketones and the quiescent affinity label concept: the departing group as a variable structural element in the design of inactivators of cysteine proteinases. Biochemistry 1991; 30:4678-4687
77. Smith RA, Coles PJ, Spencer RW et al. Peptidyl O-acyl hydroxamates: potent new inactivators of cathepsin B. Biochem Biophys Res Commun 1998; 155:1201-1206
78. Powers JC, Asgian JL, Ekici OD et al. Irreversible inhibitors of serine, cysteine and threonine proteases. Chem Rev 2002; 102:4639-4750
79. Baskin-Bey ES, Washburn K, Feng S et al. Clinical Trial ofthe Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant 2007; 7:218-225
80. Brady KD. Bimodal inhibition of caspase-1 by aryloxymethyl and acyloxymethyl ketones. Biochemistry 1998; 37:8508-8515
81. Brady KD, Giegel DA, Grinnell C et al. A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones. Bioorg Med Chem 1999; 7:621-631
82. Palmer JT, Rasnick D, Klaus JL et al. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995; 38:3193-3196
83. Engel JC, Doyle PS, McKerrow JH. Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease. Medicina (B Aires) 1999; 59:171-175
84. Barr SC, Warner KL, Kornreic BG et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005; 49:5160-5161
85. McKerrow JH, Doyle PS, Engel JC et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 2009; 104:263-269
86. Marin-Neto JA, Rassi A, Morillo CA et al. BENEFIT Investigators Am Heart J 2009; 156:37-43
87. Sterverding D, Caffrey C, Sajid M. Cysteine Proteinase Inhibitors as Therapy for Parasitic Diseases: Advances in Inhibitor Design. Mini Rev Med Chem 2006; 6:1025-1032